Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid- D-Phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 11, 1998, Pages 3790-3794

  Colao, Annamaria ^a   Lastoria, Secondo ^b   Ferone, Diego ^a   Pivonello, Rosario ^a   Macchia, Paolo E ^a   Vassallo, Patrizia ^a   Bonavolontá, Giulio ^a   Muto, Pietro ^b   Lombardi, Gaetano ^a   Fenzi, Gianfranco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PENTETREOTIDE IN 111; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCOCORTICOID; INDIUM; OCTREOTIDE; PENTETIC ACID; SDZ 215 811; SDZ 215-811;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; SCORING SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; ORBIT; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; FEMALE; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; INDIUM RADIOISOTOPES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OCTREOTIDE; ORBIT; PENTETIC ACID; PROGNOSIS; TREATMENT OUTCOME;

EID: 14444271577     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.11.5274     Document Type: Article

References (32)

1. Jacobson DH, Gorman CA. 1984 Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis and treatment. Endocr Rev. 5:200-220.
2. Bahn RS, Heufelder AE. 1993 Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 329:1468-1475.
3. Burch HB, Wartofsky L. 1993 Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 14:747-793.
4. Wall JR, Salvi M, Bernard NF, et al. 1991 Thyroid associated ophthalmopathy: a model for the association of organ-specific autoimmune disorders. Immunol Today. 12:150-153.
5. Trokel SL, Jacobiec FA. 1981 Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. Ophthalmology. 88:553-564.
6. Feldon SE. 1990 Diagnostic tests and clinical techniques in the evaluation of Graves' ophthalmopathy. In: Wall JR, How J, eds. Graves' ophthalmopathy. Boston: Blackwell Scientific; 79-93.
7. Bartalena L, Marcocci C, Bogazzi F, et al. 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 338:73-78.
8. Reubi JC, Maurer R. 1985 Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience. 15:1183-1193.
9. Patel YC, Amherdt M, Orci L. 1982 Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islet. Science. 217:1155-1156.
10. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. 1989 Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem. 264:949-953.
11. Krenning EP, Bakker WH, Breeman WAP, et al. 1989 Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1:242-245.
12. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. 1990 Somatostatin receptor imaging. N Engl J Med. 323:1246-1249.
13. Van Hagen PM, Krenning EP, Kwekkeboom DJ, et al. 1994 Somatostatin in the immune and haematopoietic system; a review. Eur J Clin Invest. 24:91-99.
14. 1]-octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab. 79:1845-1851.
15. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. 1995 Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med. 36:550-554.
16. Kahaly G, Gorges R, Diaz M, Hommel G, Bockisch A. 1998 Indium-111-pentetreotide in Graves' disease. J Nucl Med. 39:533-536.
17. Moncayo R, Dessl A, Judmaier W, et al. 1994 Octreoscan and magnetic resonance imaging of endocrine orbitopathy. Eur J Nucl Med. 21:754.
18. Krassas GE, Dumas A, Pontikides N, Kaltsas TH. 1995 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf). 42:571-580.
19. Krassas GE, Kaltsas TH, Dumas A, Pontikides N, Tolis G. 1997 Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol. 136:416-422.
20. Chang TC, Kao SCS, Huang KM. 1992 Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Br Med J. 304:158.
21. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 49:1583-1591.
22. Bartalena L, Marcocci C, Bogazzi F, et al. 1989 A new ophthalmopathy index for quantification of eye changes of Graves' disease. Acta Endocrinol (Copenh). 121[Suppl 2]:190-192.
23. Nagayama Y, Izumi M, Kirijama T, et al. 1987 Treatment of Graves' ophthalmopathy with high dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh). 116:513-518.
24. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. 1988 Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. Br Med J. 297:1574-1578.
25. Guy JR, Fagien S, Donovan JP, Rubin ML. 1989 Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology. 96:1048-1053.
26. Mourits MP, Koorneef L, Wiersinga WM, Prummel MF, Berghout A, Van der Gaag R. 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 73:639-644.
27. Kahaly G, Shuler M, Sewell AC, Bernard G, Beyer J, Krause U. 1990 Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 33:35-44.
28. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. 1995 Somatostatin receptor scintigraphy. Nucl Med Ann. 1:1-50.
29. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 20:716-731.
30. Ur E, Mather SJ, Bomanji J, et al. 1992 Pituitary imaging using a labeled somatostatin analogue in acromegaly. Clin Endocrinol (Oxf). 36:147-150.
31. Colao A, Ferone D, Lastoria S, et al. 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 81:2356-2362.
32. Borson-Chazot F, Houzard C, Ajzenberg C, et al. 1997 Somatostatin receptor in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol (Oxf). 47:589-598.